ARS Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview

ARS Pharmaceuticals

01/08/2025 12:17

ARS Pharmaceuticals Inc SPRY.OQ SPRY.O is expected to  show a rise in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The San Diego California-based  company is expected to report a 2,655.3% increase in revenue to $13.776 million from $500 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for ARS Pharmaceuticals Inc is for a loss of 47 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00, about 41.1% above its last closing price of $17.68

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.35
-0.35
-0.35
Met
-1
Dec. 31 2025
-0.10
-0.14
0.49
Beat
450
Sep. 30 2024
-0.15
-0.15
-0.20
Missed
-35.6​
Jun. 30 2024
-0.13
-0.12
-0.13
Missed
-11.4
​​Mar. 31 2024
-0.12
-0.11
-0.11
Met
0
Dec. 31 2023
-0.11
-0.14
-0.07
Beat
50​
Sep. 30 2023
-0.19
-0.18
-0.16
Beat
12.4
Jun. 30 2023
-0.19
-0.17
-0.18
Missed
-3.6

This summary was machine generated August 1 at 11:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)